Home›Trial›NCT05027477
NCT05027477NAACTIVE NOT RECRUITING

A Comparison of TULSA Procedure vs. Radical Prostatectomy in Participants With Localized Prostate Cancer

Study Summary

Men with localized, intermediate risk prostate cancer will be randomized to undergo either radical prostatectomy or the TULSA procedure, with a follow-up of 10 years in this multi-centered randomized control trial. This study will determine whether the TULSA procedure is as effective and more safe compared to radical prostatectomy.

Conditions
Prostate CancerProstate Adenocarcinoma
Interventions / Drugs
Radical ProstatectomyTULSA Procedure
View on ClinicalTrials.gov ↗
Sponsor
PRN
Profound Medical
TULSA-PRO Prostate
D46/100
Study Details
Enrollment201 participants
Primary Completion—
Lead SponsorProfound Medical Inc.
Data Retrieved2026-04-11 04:24:51.229898+00:00
What This Trial Means for Biotech Investors
Trial Phase Context

This trial phase represents an early or specialized stage of clinical development.

Status & Expected Data

Enrollment is complete. The trial is in its follow-up or data collection phase — a readout may occur on or near the primary completion date.

Enrolled: 201 participants
Sponsor Catalyst Profile

Profound Medical (PRN) is the sponsoring company for this trial. BiotechSign currently grades this company D (46/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.

PRN Full Pipeline →All Companies →
Not financial advice. BiotechSign data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.